Microsoft word - kppi front sheet mar 13.doc

Agenda item 2013/21
DATE OF GOVERNING BODY MEETING:
Category of Paper
Governing Body Lead:
Decision and Approval
Dr Akram Khan
Clinical Board Lead
Position Statement
Dr. Ishtiaq Gilkar
Paper Author:
Information
Tracy Gaston CCG Pharmacist
Paper Title:
Confidential Discussion
Prescribing Incentive Scheme
SUMMARY

1)
For many years high quality prescribing has been incentivised through a reward scheme. Typically the scheme changes each year to ensure continuous improvement is incentivised. Schemes usually identify areas where practices are outliers within national benchmarks or where there is variation or clear room for improvement. The proposed scheme has ten key prescribing performance indicators(KPPIs) and sets out a target for each one. The KPPIs reflect quality and/or efficiency savings. To achieve the reward payments practices have to demonstrate that they have fulfilled the criteria set within the indicators. Some indicators stand alone. Others are grouped together. All indicators within a group have to be achieved in order to gain points. Some markers are carried over from last year’s scheme with slight modifications, numbers 1, 2 and 3. Others, 4 and 5 cover areas from the 2012/13 scheme but from a different angle and the remainder are new. The majority are in line with nationally published recommendations from the National Prescribing Centre and Scottish Therapeutic Indicators(exceptions being 4,5 and 9)
BACKGROUND

KPPIs have for a number of years been used to promote quality and productivity in
primary care prescribing. They have been important in the delivery of QIPP savings.
NHS Bradford City CCG has a good record on delivering on the markers with
improvements being made as the year progresses.
IMPACT ON STRATEGIC OBJECTIVES

The KPPIs support our overall strategic objectives, specifically patient safety, and
improving quality in primary care.

FINANCIAL IMPLICATIONS
There are potential savings of approximately £810,000 for both City and District CCG’s. The
cost of the scheme for City will be a maximum of £237,000 with potential saving of
£210,000. Practices are awarded a maximum of £2 per patient, achieved from 20p per
patient per marker reached.

COMMUNICATIONS AND INVOLVEMENT

The indicators have been developed by the CCG Prescribing Group having taken
feedback from Practices through prescribing visits, cluster meetings, practice workshops,
forums etc.
EQUALITY IMPACT ASSESSMENT

There are no adverse impacts on any patient groups as a result of this incentive
scheme. Practices have been invited to contribute through the Prescribing Group in
developing these indicators.
RECOMMENDATION
The Governing Body is invited to approve the prescribing incentive scheme for

APPENDICES

Appendix 1 The prescribing incentive scheme summary and rationale.
Back ground reading available to governing body members.

AND

No prescriptions for
combination
products after 30th
June 2013
a) Ezetimibe as a % ≤ 2% of all statin b) Rosuvastatin as a ≤ 4% of all statin % of the total statin AND

c) No prescriptions
of Omacor after 30th
June 2013
with comments by the team for all items over £200 and justification if special to continue continued only if the
person shows a reduction in HbA1c of at least 5.5 mmol/mol (0.5%) at six months. appropriate, revise prescribing of antidepressants in adults to ensure that it is in line with NICE guidance.

Source: http://www.bradfordcityccg.nhs.uk/wp-content/uploads/2013/02/2013-21-Prescribing-KPPIv2.pdf